Evidence map›Paper›PMID 31803622›Full record

ArticleFrontiers in oncology2019

Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis.

Ingrid Dubois-Vedrenne, Olivier De Henau, Virginie Robert, Francina Langa, Joaquim Javary, Diana Al Delbany, Olivier Vosters, Edgar Angelats-Canals, Maxime Vernimmen, Souphalone Luangsay and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Adipokines in the Skin and in Dermatological Diseases.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Ingrid Dubois-VedrenneIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Olivier De HenauIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Virginie RobertIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Francina LangaCentre d'Ingénierie Génétique Murine (CIGM), Institut Pasteur, Paris, France.
Joaquim JavaryIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Diana Al DelbanyIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Olivier VostersIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Edgar Angelats-CanalsIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Maxime VernimmenIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Souphalone LuangsayIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Valérie WittamerIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.
Marc ParmentierIRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemerin is a multifunctional protein acting mainly through the G protein-coupled receptor ChemR23/CMKLR1/Chemerin

Indexed as

chemerinchemical carcinogenesisChemR23CMKLR1squamous cell carcinoma

Identifiers

PMID31803622
PMCPMC6873210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.